You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

CLINICAL TRIALS PROFILE FOR FLUTEMETAMOL F-18


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Flutemetamol F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01028053 ↗ Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed i3 Research Phase 3 2009-12-01 This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗ Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed i3 Statprobe Phase 3 2009-12-01 This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗ Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed Medpace, Inc. Phase 3 2009-12-01 This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Flutemetamol F-18

Condition Name

Condition Name for Flutemetamol F-18
Intervention Trials
Alzheimer's Disease 8
Mild Cognitive Impairment 6
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Flutemetamol F-18
Intervention Trials
Alzheimer Disease 11
Cognitive Dysfunction 8
Cognition Disorders 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Flutemetamol F-18

Trials by Country

Trials by Country for Flutemetamol F-18
Location Trials
United States 10
France 2
Switzerland 2
Netherlands 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Flutemetamol F-18
Location Trials
New Jersey 5
Utah 3
New York 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Flutemetamol F-18

Clinical Trial Phase

Clinical Trial Phase for Flutemetamol F-18
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Flutemetamol F-18
Clinical Trial Phase Trials
Completed 7
Terminated 5
Unknown status 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Flutemetamol F-18

Sponsor Name

Sponsor Name for Flutemetamol F-18
Sponsor Trials
GE Healthcare 8
i3 Statprobe 5
University of Utah 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Flutemetamol F-18
Sponsor Trials
Industry 20
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Flutemetamol F 18: Clinical Trials, Market Analysis, and Projections

Introduction

Flutemetamol F 18, marketed as Vizamyl by GE Healthcare, is a diagnostic radiopharmaceutical used in positron emission tomography (PET) imaging to detect β-amyloid neuritic plaques in the brain. This is a critical marker for Alzheimer's disease and other cognitive impairments. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Phase 3 Trials and Multicenter Cohort Studies

Several clinical trials have been conducted to evaluate the efficacy and safety of flutemetamol F 18. A notable multicenter cohort study involved patients with amnestic mild cognitive impairment (aMCI) who underwent PET scans at baseline and were followed up every 6 months for up to 3 years. This study aimed to assess the risk of progression from aMCI to probable Alzheimer's disease (AD)[1].

Sensitivity and Specificity

A phase 3 trial focused on determining the sensitivity and specificity of flutemetamol F 18 PET imaging in detecting β-amyloid in the brain. The study involved terminally ill patients and used neuropathologically determined neuritic plaque levels as the standard of truth. The results showed high sensitivity (81-93%) and specificity (88%) for detecting β-amyloid plaques[4].

Safety and Efficacy

The clinical trials have consistently shown that flutemetamol F 18 is safe and effective. The drug has been administered intravenously at a dose of 185 MBq (5 mCi) without significant adverse effects. The imaging was performed approximately 90 minutes after administration, and the scans were interpreted by blinded readers to ensure objectivity[3][4].

Market Analysis

Current Market Position

Flutemetamol F 18 has been approved by the FDA for use in PET imaging to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment. This approval has positioned Vizamyl as a valuable tool in the diagnostic arsenal for Alzheimer's disease and other cognitive decline conditions[2][3].

Market Demand

The demand for diagnostic tools in neurology, particularly for Alzheimer's disease, is increasing due to the growing prevalence of the disease and the need for early and accurate diagnosis. Flutemetamol F 18 fills this gap by providing a reliable method for detecting β-amyloid plaques, which are a hallmark of Alzheimer's disease.

Competitive Landscape

The market for PET imaging agents is competitive, with other agents like florbetapir and florbetaben also available. However, flutemetamol F 18 has demonstrated strong concordance with neuropathological findings and high sensitivity and specificity, making it a preferred choice in many clinical settings[5].

Projections and Future Outlook

Market Growth

The market for diagnostic imaging agents in neurology is expected to grow significantly in the coming years. As the global population ages, the incidence of Alzheimer's disease and other cognitive impairments will increase, driving the demand for accurate diagnostic tools like flutemetamol F 18.

Technological Advancements

Advancements in PET imaging technology and the integration of artificial intelligence in image analysis are expected to enhance the accuracy and efficiency of flutemetamol F 18 scans. This could further solidify its position in the market.

Regulatory Environment

Regulatory approvals and guidelines will continue to play a crucial role in the market success of flutemetamol F 18. Ongoing support from regulatory bodies and updates in clinical guidelines will help in expanding its use and acceptance.

Clinical Implications

Early Diagnosis and Management

Flutemetamol F 18 enables early detection of β-amyloid plaques, which is critical for the early diagnosis and management of Alzheimer's disease. Early diagnosis can lead to better patient outcomes and more effective treatment strategies.

Combination with Other Biomarkers

Studies have shown that combining flutemetamol F 18 PET scans with other biomarkers, such as hippocampal volume measurements, can provide a more comprehensive assessment of the risk of progression to Alzheimer's disease[1].

Key Takeaways

  • High Sensitivity and Specificity: Flutemetamol F 18 has demonstrated high sensitivity and specificity in detecting β-amyloid plaques.
  • Safety Profile: The drug has been shown to be safe with no significant adverse effects.
  • Market Demand: Growing demand for diagnostic tools in neurology due to the increasing prevalence of Alzheimer's disease.
  • Competitive Advantage: Strong concordance with neuropathological findings and high accuracy make it a preferred choice.
  • Future Outlook: Expected market growth driven by an aging population and technological advancements.

FAQs

Q: What is flutemetamol F 18 used for?

A: Flutemetamol F 18 is used in PET imaging to detect β-amyloid neuritic plaques in the brain, which is a hallmark of Alzheimer's disease and other cognitive impairments.

Q: How is flutemetamol F 18 administered?

A: It is administered intravenously at a dose of 185 MBq (5 mCi) and imaging is performed approximately 90 minutes later[3].

Q: What are the key findings from the clinical trials?

A: The trials have shown high sensitivity (81-93%) and specificity (88%) for detecting β-amyloid plaques, and the drug has been found to be safe with no significant adverse effects[4].

Q: How does flutemetamol F 18 compare to other PET imaging agents?

A: It has demonstrated strong concordance with neuropathological findings and high accuracy, making it a preferred choice in many clinical settings[5].

Q: What is the future outlook for the market of flutemetamol F 18?

A: The market is expected to grow due to the increasing prevalence of Alzheimer's disease and technological advancements in PET imaging.

Sources

  1. JAMA Neurology: "Use of Flutemetamol F 18–Labeled PET and Other Biomarkers to Assess the Risk of Progression from Amnestic Mild Cognitive Impairment to Probable Alzheimer Disease"[1].
  2. FDA: "NDA 203137: Flutemetamol F 18 Injection"[2].
  3. FDA: "Clinical Review: Vizamyl (Flutemetamol F18 Injection)"[3].
  4. PubMed: "Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 to detect β-amyloid in the brain"[4].
  5. AuntMinnie: "GE reports on flutemetamol PET study"[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.